Marina Biotech ($MRNA) raises $3.3 million

Marina Biotech ($MRNA) of Bothell, WA, which develops RNAi-based compounds and drug delivery technologies, has raised $3.3 million through a securities offering.

Xconomy reports that investors who bought 1.8 million shares at $1.84 each also got a subscription unit to buy another 2.4 million shares over the next 16 months for no more than $2.21 a share. If those shares are bought, the company could raise another $5.4 million. Marina does many things in the RNAi space, including figuring out a way to make sure RNA-based therapeutics are delivered to the right location.

Marina acquired the rights to Smarticles drug-delivery technology from Germany's Novosom in exchange for $5 million in common stock. Smarticles are the basis for ProNAi Therapeutics' anti-tumor drug candidate, PNT2258, which recently launched Phase I clinical trials in Texas.

- read the Xconomy brief
- and here's our background on the company

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.